All In MedTech

Device Trial Radar · NCT02042404

The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study

Last checked: Nov 20, 2026Latest source record: Feb 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

48

Actual

Start

Mar 2014

Primary completion

Jan 2015

Study completion Mar 2015

Sponsor

Lead sponsor
EarLens CorporationNot on our public-company list
Sponsor type
Industry
First posted
Jan 22, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The EarLens System is an assistive hearing device that is intended to provide amplification for the treatment of patients with sensorineural hearing impairment. The purpose of this multi-center definitive study is to assess the safety and efficacy of the EarLens System for subjects with bilateral mild to severe sensorineural hearing impairments wearing the fully activated system in their daily lives for a 4 month period of time. This study is designed to support US and International marketing applications to commercialize the EarLens System. The main efficacy hypothesis is that the EarLens System will be shown to improve speech understanding in quiet.

Conditions

  • Hearing Impairment

Interventions

  • Sound amplification provided via EarLens System.Device

    The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Mean Aided Word Recognition Scores (WRS) When Compared to the Baseline Unaided Condition.Time frame: Baseline and 30 days
  2. Audiometric Safety as Shown by no Hearing Change Pre and Post TreatmentTime frame: Baseline and 120 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • EarLens Corporation

    Menlo Park, California

  • Camino Ear Nose and Throat Clinic

    San Jose, California

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.